Switch theme
Sign up to access all valuation multiples
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates most of its revenue through prescription Kampo products, followed by over-the-counter medicines. Tsumura promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company considers strategic collaboration agreements to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
1936
4.2K+
LTM Revenue $1.3B
LTM EBITDA $345M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tsumura has a last 12-month revenue (LTM) of $1.3B and a last 12-month EBITDA of $345M.
In the most recent fiscal year, Tsumura achieved revenue of $1.0B and an EBITDA of $239M.
Tsumura expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tsumura valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $626M | XXX | $472M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | $345M | XXX | $239M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $273M | XXX | $137M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $216M | XXX | $115M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $11.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tsumura's stock price is JPY 3413 (or $23).
Tsumura has current market cap of JPY 257B (or $1.8B), and EV of JPY 254B (or $1.7B).
See Tsumura trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.8B | XXX | XXX | XXX | XXX | $2.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tsumura has market cap of $1.8B and EV of $1.7B.
Tsumura's trades at 1.7x EV/Revenue multiple, and 7.3x EV/EBITDA.
Equity research analysts estimate Tsumura's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tsumura has a P/E ratio of 8.1x.
See valuation multiples for Tsumura and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 5.0x | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBIT | 6.4x | XXX | 12.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.1x | XXX | 15.4x | XXX | XXX | XXX |
| EV/FCF | 56.5x | XXX | -24.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTsumura's last 12 month revenue growth is 6%
Tsumura's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Tsumura's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tsumura's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tsumura and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tsumura acquired XXX companies to date.
Last acquisition by Tsumura was XXXXXXXX, XXXXX XXXXX XXXXXX . Tsumura acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tsumura founded? | Tsumura was founded in 1936. |
| Where is Tsumura headquartered? | Tsumura is headquartered in Japan. |
| How many employees does Tsumura have? | As of today, Tsumura has 4.2K+ employees. |
| Who is the CEO of Tsumura? | Tsumura's CEO is Mr. Terukazu Kato. |
| Is Tsumura publicy listed? | Yes, Tsumura is a public company listed on TKS. |
| What is the stock symbol of Tsumura? | Tsumura trades under 4540 ticker. |
| When did Tsumura go public? | Tsumura went public in 1980. |
| Who are competitors of Tsumura? | Similar companies to Tsumura include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tsumura? | Tsumura's current market cap is $1.8B |
| What is the current revenue of Tsumura? | Tsumura's last 12 months revenue is $1.3B. |
| What is the current revenue growth of Tsumura? | Tsumura revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Tsumura? | Current revenue multiple of Tsumura is 1.4x. |
| Is Tsumura profitable? | Yes, Tsumura is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tsumura? | Tsumura's last 12 months EBITDA is $345M. |
| What is Tsumura's EBITDA margin? | Tsumura's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Tsumura? | Current EBITDA multiple of Tsumura is 5.0x. |
| What is the current FCF of Tsumura? | Tsumura's last 12 months FCF is $30.8M. |
| What is Tsumura's FCF margin? | Tsumura's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Tsumura? | Current FCF multiple of Tsumura is 56.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
